Nektar Therapeutics (NKTR) EBT Margin (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly EBT Margin of 396.74% for Q1 2026, up 4656.0% year-over-year from 8.34% in Q1 2025, and down 149.31% quarter-over-quarter from 159.13% in Q4 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) EBT Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 396.74% for Q1 2026.
- In Q1 2026, EBT Margin rose 4656.0% year-over-year to 396.74%; the TTM figure through Mar 2026 stood at 273.59% (down 12605.0% YoY), while the FY2025 annual figure was 281.52%, down 16041.0% from the prior year.
- EBT Margin for Q1 2026 stood at 396.74%, down from 159.13% in the prior quarter.
- The five-year high for EBT Margin was 24.0% in Q4 2024, with the low at 736.47% in Q2 2022.
- The 5-year median for EBT Margin is 250.6% (2022), against an average of 295.86%.
- The sharpest annual moves came in 2022 and 2023: EBT Margin slumped 177137 bps in 2022, then soared 48686 bps in 2023.
- Nektar Therapeutics' EBT Margin stood at 256.75% in 2022, then surged by 31 bps to 176.29% in 2023, then jumped by 114 bps to 24.0% in 2024, then tumbled by 763 bps to 159.13% in 2025, then sank by 149 bps to 396.74% in 2026.
- Business Quant data shows NKTR's EBT Margin at 396.74% in Q1 2026, 159.13% in Q4 2025, and 297.04% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn | -397.80% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -397.80% |
| Mar 31, 2026 | -396.74% |
| Dec 31, 2025 | -159.13% |
| Sep 30, 2025 | -297.04% |
| Jun 30, 2025 | -352.53% |
| Mar 31, 2025 | -443.30% |
| Dec 31, 2024 | 24.00% |
| Sep 30, 2024 | -153.57% |
| Jun 30, 2024 | -222.73% |
| Mar 31, 2024 | -170.23% |
| Dec 31, 2023 | -176.29% |
| Sep 30, 2023 | -190.10% |
| Jun 30, 2023 | -249.62% |
| Mar 31, 2023 | -634.81% |
| Dec 31, 2022 | -288.16% |
| Sep 30, 2022 | -250.60% |
| Jun 30, 2022 | -736.47% |
| Mar 31, 2022 | -363.66% |
| Dec 31, 2021 | -587.02% |
| Sep 30, 2021 | -520.02% |